Thr58
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr58  -  N-Myc (human)

Site Information
KkFELLPtPPLsPsr   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448223
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 5 ) , immunoprecipitation ( 7 , 36 ) , mass spectrometry ( 3 , 4 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 37 ) , mutation of modification site ( 7 , 36 ) , phospho-antibody ( 1 , 2 , 36 ) , western blotting ( 1 , 2 , 7 , 36 )
Disease tissue studied:
breast cancer ( 8 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 ) , leukemia ( 19 ) , acute myelogenous leukemia ( 19 ) , lung cancer ( 9 , 10 , 11 , 12 , 13 ) , non-small cell lung cancer ( 11 , 12 ) , non-small cell lung adenocarcinoma ( 11 , 12 , 13 ) , non-small cell large cell lung carcinoma ( 11 ) , non-small cell squamous cell lung carcinoma ( 13 ) , small-cell lung cancer ( 9 , 10 ) , neuroblastoma ( 1 , 5 , 7 , 17 , 36 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 35 ) , 293 (epithelial) ( 2 ) , 293E (epithelial) ( 27 ) , 293GP (epithelial) [NPM-ALK (human), transfection] ( 34 ) , breast ( 3 ) , Calu-3 (pulmonary) ( 12 ) , DMS53 (pulmonary) ( 10 ) , DMS79 (pulmonary) ( 9 ) , HCC15 (pulmonary) ( 13 ) , HCC827 (pulmonary) ( 12 ) , HeLa (cervical) ( 6 , 16 , 29 , 30 , 31 , 32 , 33 , 37 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HUES-9 ('stem, embryonic') ( 28 ) , IMR32 (neural crest) ( 7 , 36 ) , Jurkat (T lymphocyte) ( 14 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ) , K562 (erythroid) ( 16 ) , KG-1 (myeloid) ( 19 ) , LOU-NH91 (squamous) ( 13 ) , lung ( 9 , 10 , 11 , 12 , 13 ) , NB10 (neural crest) ( 17 ) , NCI-H128 (pulmonary) ( 9 ) , NCI-H1299 (pulmonary) ( 11 ) , NCI-H1417 (pulmonary) ( 9 ) , NCI-H1650 (pulmonary) ( 12 ) , NCI-H1703 (squamous) ( 13 ) , NCI-H1734 (pulmonary) ( 11 ) , NCI-H1944 (pulmonary) ( 11 ) , NCI-H1975 (pulmonary) ( 12 ) , NCI-H2073 (pulmonary) ( 13 ) , NCI-H209 (pulmonary) ( 9 ) , NCI-H2106 (pulmonary) ( 12 ) , NCI-H2342 (pulmonary) ( 13 ) , NCI-H358 (pulmonary) ( 11 ) , NCI-H446 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 11 ) , NCI-H524 (pulmonary) ( 9 ) , NCI-H526 (pulmonary) ( 10 ) , NCI-H69 (pulmonary) ( 10 ) , NCI-H82 (pulmonary) ( 10 ) , NPC (neural crest) ( 17 ) , SH-SY5Y (neural crest) ( 1 ) , SHEP (neuron) ( 7 , 36 ) , SK-N-BE(2) (neural crest) ( 1 ) , SKNDZ (neural crest) ( 5 ) , TGW (neuron) ( 5 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Regulatory protein:
N-Myc (human) ( 36 )
Putative in vivo kinases:
GSK3B (human) ( 5 )
Treatments:
angiotensin_2 ( 35 ) , BIO ( 5 ) , HA1077 ( 1 ) , LY294002 ( 36 ) , MG132 ( 36 ) , nocodazole ( 36 ) , selumetinib ( 4 ) , siRNA ( 36 ) , vemurafenib ( 4 )

Downstream Regulation
Effects of modification on N-Myc:
intracellular localization ( 5 ) , molecular association, regulation ( 5 , 36 ) , protein degradation ( 5 , 7 ) , ubiquitination ( 5 , 36 )
Induce interaction with:
AurA (human) ( 36 ) , TRIM32 (human) ( 5 )

References 

1

Dyberg C, et al. (2017) Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 114, E6603-E6612
28739902   Curated Info

2

Eberhardt A, et al. (2016) Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget 7, 63629-63639
27571165   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

5

Izumi H, Kaneko Y (2014) Trim32 Facilitates Degradation of MYCN on Spindle Poles and Induces Asymmetric Cell Division in Human Neuroblastoma Cells. Cancer Res 74, 5620-30
25100564   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Gustafson WC, et al. (2014) Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer Cell 26, 414-27
25175806   Curated Info

8

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

15

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

18

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

19

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

20

Mulhern D (2011) CST Curation Set: 12640; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

21

Mulhern D (2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

22

Mulhern D (2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

23

Mulhern D (2011) CST Curation Set: 12440; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

24

Mulhern D (2011) CST Curation Set: 12442; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

25

Mulhern D (2011) CST Curation Set: 12443; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

26

Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

27

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

28

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

29

Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

30

Zhou J (2010) CST Curation Set: 10710; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

31

Zhou J (2010) CST Curation Set: 10713; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

32

Zhou J (2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

33

Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

34

Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32
20393185   Curated Info

35

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

36

Otto T, et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78
19111882   Curated Info

37

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info